Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA

Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA

Bibliographic Details
Main Authors:	Lang Zheng, Wenjing Wang, Qiu Sun
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-02-01
Series:	Signal Transduction and Targeted Therapy
Online Access:	https://doi.org/10.1038/s41392-024-01770-y

Similar Items

Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016–2020
by: Jing Luo, et al.
Published: (2023-02-01)

Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
by: Alexander C. Martins, et al.
Published: (2024-09-01)

Development on Cancer Therapeutic Drugs Approved by FDA in 2023
by: Qing HUANG, et al.
Published: (2024-07-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation
by: Megan C. Herink, et al.
Published: (2022-09-01)

The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2024-01-01)

Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023
by: Maria Novella Romanelli, et al.
Published: (2023-12-01)

An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)
by: Josh Elbaz, et al.
Published: (2024-04-01)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023-11-01)

FDA APPROVES NEW HEMOPHILIA DRUG
by: article Editorial
Published: (2025-02-01)

In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
by: Ridwan Abiodun Salaam, et al.
Published: (2025-03-01)

Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review
by: Senthil Lingaratnam, et al.
Published: (2024-12-01)

FDA approved injection drug against schizophrenia
by: article Editorial
Published: (2023-07-01)

Synthesis and clinical application of new drugs approved by FDA in 2022
by: Jing-Yi Zhang, et al.
Published: (2023-09-01)

Celebrating breakthrough in dental diagnostics: FDA approval of an AI model for diagnosis of periodontal diseases: A correspondence
by: Ayesha Khan, et al.
Published: (2023-09-01)

FDA-approved drugs in 2022: A brief outline
by: Haitham Ahmed Al-Madhagi
Published: (2023-03-01)

Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1
by: Emanuele Criscuolo, et al.
Published: (2023-12-01)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
by: Juliana T. W. Tong, et al.
Published: (2021-09-01)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
by: Ghulam Shabir, et al.
Published: (2023-08-01)

Ebanga™: The most recent FDA-approved drug for treating Ebola
by: Elahe Taki, et al.
Published: (2023-03-01)

FDA HAS APPROVED NEW DRUG TREATMENT FOR HIV IN CHILDREN
by: article Editorial
Published: (2024-05-01)

FDA APPROVED A NEW DRUG FOR THE TREATMENT OF ATOPIC DERMATITIS
by: article Editorial
Published: (2024-09-01)

The FDA has approved a new drug for the treatment of leukemia
by: article editorial
Published: (2024-12-01)

The FDA has approved the first medical drug for Rett syndrome
by: article Editorial
Published: (2023-05-01)

FDA Has Approved First Drug for Treatment of Congenital Athymia
by: article Editorial
Published: (2021-12-01)

FDA-Approved Antibacterials and Echinocandins
by: Othman Al Musaimi
Published: (2025-02-01)

FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01)

An insider's perspective on FDA approval of aducanumab
by: Yaning Wang
Published: (2023-04-01)

Shape-based reprofiling of FDA-approved drugs for the H₁ histamine receptor.
by: Vasudevan, SR, et al.
Published: (2012)

Management of Facial Burn Scar using Repurposed FDA-Approved Drugs
by: Mohamed El Masry, MD, PhD, et al.
Published: (2024-09-01)

Selumetinib—A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis
by: Surajit Gorai, et al.
Published: (2024-06-01)

DRUG SAFETY ASSESSMENT FOR CENOBAMATE A RECENTLY FDA-APPROVED ANTIEPILEPTIC
by: Beatrice Radu, et al.
Published: (2023-10-01)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
by: Mohini Chaurasia, et al.
Published: (2023-07-01)

FDA HAS APPROVED NEW DRUG TREATMENT FOR DUCHENE MUSCULAR DYSTROPHY
by: article Editorial
Published: (2024-05-01)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
by: Débora Nunes, et al.
Published: (2022-10-01)

An overview of FDA-approved vaccines & their innovators
by: Rebekah H. Griesenauer, et al.
Published: (2017-12-01)

In Silico Drug Repurposing Approach: Investigation of <i>Mycobacterium tuberculosis</i> FadD32 Targeted by FDA-Approved Drugs
by: Nolwazi Thobeka Portia Ngidi, et al.
Published: (2022-01-01)

The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2025-01-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
by: Tarek Abd El-Hafeez, et al.
Published: (2024-01-01)